Processing your payment...
Please do not close your browser.

Osteoarthritis Pain Drugs Market Growth, Trends and Forecast (2022 - 2029) By Drug Class (NSAIDs, Opioids, Viscosupplements, Corticosteroids, and Others) Route of Administration (Oral, Parenteral, and Topical) and By Regions

12 Jul, 2022 | 175 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Osteoarthritis Pain Drugs Market will register a CAGR of 6.1 % in terms of revenue and the global market size will reach USD 13.8 Billion by 2029.

Osteoarthritis Pain Drugs Market Overview

One of the most prevalent chronic disorders of the joint is osteoarthritis (OA), commonly referred to as degenerative joint disease or degenerative arthritis. Any joint in the neck, lower back, hips, or knees might have OA. When a person has OA, the cartilage that normally provides a smooth, gliding surface for joint mobility wears off, leading to discomfort, swelling, and other problems with how the body's joints move. Painkillers for osteoarthritis are used to lessen the discomfort experienced by OA patients. According to data from the Arthritis Foundation, osteoarthritis (OA), which affects around 27 million Americans, is the most prevalent chronic ailment of the joints. Because of its significant prevalence, OA pain medications are required.

The market is primarily driven by elements like a potent pipeline portfolio and the rising prevalence of OA worldwide. Osteoarthritis is currently one of the 10 most incapacitating illnesses in developed nations, according to the World Health Organization. According to the WHO, 9.6 percent of men and 18.0 percent of women over 60 have symptomatic osteoarthritis, according to global figures for the disease. 80 percent of those with osteoarthritis will have movement restrictions, and 25 percent won't be able to carry out their primary daily duties. However, the adverse effects of the medications and the loss of branded medicines' patent protection may limit the market's expansion.

What is our Osteoarthritis Pain Drugs Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 6.1 % during the review period (2022 to 2029).

 

By Drug Class

  • NSAIDs
  • Opioids
  • Viscosupplements
  • Corticosteroids
  • Others

 

By Route of Administration

 

 

 

 

  • Oral
  • Parenteral
  • and Topical) and By Dosage form (Solid
  • Liquid
  • Semi-solid

 

 

 

By Companies

  • Pfizer Inc.
  • Abbott
  • Eli Lilly and Company
  • ABIOGEN PHARMA
  • S.p.A. Horizon Pharma plc.
  • Ferring B.V.
  • Merck Sharp & Dohme Corp.
  • Medivir
  • Bioventus Inc.
  • Sanofi

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

175

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Osteoarthritis Pain Drugs Market during the forecast period (2022-2029)?

The Osteoarthritis Pain Drugs Market is growing at a CAGR of 6.1 % over the next 7 years.

Who are the key players in Osteoarthritis Pain Drugs Market?

Zoetis Inc, Merck & Company Inc., Boehringer Ingelheim GmbH, Elanco Animal Health Inc., Vetoquinol SA, Virbac SA, Phibro Animal Health Corporation, Ceva Sante Animale S.A, Covetrus Inc., Biogenesis Bago SA, Neogen Corporation Ltd., Dechra Pharmaceuticals PLC, ImmuCell Corporation, Krka, tovarna zdravil, d. d., Novo mesto, ECO Animal Health Ltd, Others.

What region does this Osteoarthritis Pain Drugs Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What are the significant Drug classes in the Osteoarthritis Pain Drugs Market?

NSAIDs, Opioids, Viscosupplements, Corticosteroids, and Others.

What is the significant Route of Administration in the Osteoarthritis Pain Drugs Market?

Oral, Parenteral, and Topical.

Who are the Major Players in Osteoarthritis Pain Drugs Market?

Market Growth Reports lists out all the Osteoarthritis Pain Drugs Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Pfizer Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA, S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Sanofi, Others

Industry News:

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

NEW YORK & INDIANAPOLIS- Pfizer Inc. and Eli Lilly and Company announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 against it. Tanezumab 2.5 mg administered subcutaneously (SC) every eight weeks is being evaluated for the treatment of moderate-to-severe osteoarthritis (OA) pain in adult patients for whom the use of other analgesics is ineffective or not appropriate. Tanezumab is an investigational monoclonal antibody in a new class of medicines called nerve growth factor (NGF) inhibitors, which work differently than currently available treatments such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and other analgesics. In studies to date, tanezumab has not demonstrated a risk of addiction, misuse, or dependence.

What are the major Drug classes and Route of Administration for the Osteoarthritis Pain Drugs Market?

By Drug Class, it is segmented into

  • NSAIDs
  • Opioids
  • Viscosupplements
  • Corticosteroids
  • Others

By Route of Administration, it is segmented into

  • Oral
  • Parenteral
  • and Topical) and By Dosage form (Solid
  • Liquid
  • Semi-solid

Osteoarthritis Pain Drugs Market Regional Analysis

Due to the U.S.'s widespread adoption of Visco supplementation agents and the existence of significant players in the area, North America controls the worldwide market for osteoarthritis medications. One in five persons in the United States has arthritis, according to the Centers for Disease Control and Prevention. This percentage is predicted to rise to at least 67 percent by 2030 as the nation's population matures. One of the main factors propelling the market in North America is the increasing prevalence of osteoarthritis, which is a primary cause of disability and calls for sophisticated treatments and disease-modifying medications.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL OSTEOARTHRITIS PAIN DRUGS MARKET BY DRUG CLASS
    3. GLOBAL OSTEOARTHRITIS PAIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. OSTEOARTHRITIS PAIN DRUGS MARKET GROWTH
    4. APPLICATION OF OSTEOARTHRITIS PAIN DRUGS MARKET IMPACT OF COVID 19
  5. GLOBAL OSTEOARTHRITIS PAIN DRUGS MARKET, BY DRUG CLASS
    1. INTRODUCTION
    2. NSAIDS
    3. OPIOIDS
    4. VISCOSUPPLEMENTS
    5. CORTICOSTEROIDS
    6. OTHERS
  6. GLOBAL OSTEOARTHRITIS PAIN DRUGS MARKET, BY ROUTE OF ADMINISTRATION
    1. INTRODUCTION
    2. ORAL
    3. PARENTERAL
    4. AND TOPICAL) AND BY DOSAGE FORM (SOLID
    5. LIQUID
    6. SEMI-SOLID
  7. GLOBAL OSTEOARTHRITIS PAIN DRUGS MARKET, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. PFIZER INC.
      2. ABBOTT
      3. ELI LILLY AND COMPANY
      4. ABIOGEN PHARMA
      5. S.P.A. HORIZON PHARMA PLC.
      6. FERRING B.V.
      7. MERCK SHARP & DOHME CORP.
      8. MEDIVIR
      9. BIOVENTUS INC.
      10. SANOFI

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla